JP2023539107A - アクチビンａアンタゴニストによる心機能障害及びｃｏｖｉｄ－１９の予防及び治療方法 - Google Patents

アクチビンａアンタゴニストによる心機能障害及びｃｏｖｉｄ－１９の予防及び治療方法 Download PDF

Info

Publication number
JP2023539107A
JP2023539107A JP2023512094A JP2023512094A JP2023539107A JP 2023539107 A JP2023539107 A JP 2023539107A JP 2023512094 A JP2023512094 A JP 2023512094A JP 2023512094 A JP2023512094 A JP 2023512094A JP 2023539107 A JP2023539107 A JP 2023539107A
Authority
JP
Japan
Prior art keywords
activin
antibody
antigen
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512094A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022040461A5 (https=
JP2023539107A5 (https=
Inventor
デーヴィッド・グラス
スコット・マクドネル
ジェイク・メグナ
ローリ・モートン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023539107A publication Critical patent/JP2023539107A/ja
Publication of JPWO2022040461A5 publication Critical patent/JPWO2022040461A5/ja
Publication of JP2023539107A5 publication Critical patent/JP2023539107A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023512094A 2020-08-20 2021-08-19 アクチビンａアンタゴニストによる心機能障害及びｃｏｖｉｄ－１９の予防及び治療方法 Pending JP2023539107A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063068251P 2020-08-20 2020-08-20
US63/068,251 2020-08-20
US202063111394P 2020-11-09 2020-11-09
US63/111,394 2020-11-09
US202163139234P 2021-01-19 2021-01-19
US63/139,234 2021-01-19
PCT/US2021/046765 WO2022040461A1 (en) 2020-08-20 2021-08-19 Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists

Publications (3)

Publication Number Publication Date
JP2023539107A true JP2023539107A (ja) 2023-09-13
JPWO2022040461A5 JPWO2022040461A5 (https=) 2024-08-26
JP2023539107A5 JP2023539107A5 (https=) 2024-08-26

Family

ID=77774983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512094A Pending JP2023539107A (ja) 2020-08-20 2021-08-19 アクチビンａアンタゴニストによる心機能障害及びｃｏｖｉｄ－１９の予防及び治療方法

Country Status (10)

Country Link
US (2) US20220056119A1 (https=)
EP (1) EP4200017A1 (https=)
JP (1) JP2023539107A (https=)
KR (1) KR20230051683A (https=)
CN (1) CN116249713A (https=)
AU (1) AU2021327238A1 (https=)
CA (1) CA3189147A1 (https=)
IL (1) IL300362A (https=)
MX (1) MX2023001734A (https=)
WO (1) WO2022040461A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528232A (ja) * 2013-07-30 2016-09-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗アクチビンａ抗体及びその使用
WO2018009732A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2019005963A1 (en) * 2017-06-27 2019-01-03 The University Of Chicago USE OF ACTIVIN TO DETECT POST-PARTUM CARDIAC DYSFUNCTION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
PT3286206T (pt) * 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
CA3052625A1 (en) * 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
FI3600415T3 (fi) * 2017-03-24 2025-12-05 Novartis Ag Aktiviinireseptorin tyypin ii reseptorin vastainen vasta-aine käytettäväksi sydämen vajaatoiminnan hoidossa

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528232A (ja) * 2013-07-30 2016-09-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗アクチビンａ抗体及びその使用
WO2018009732A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2019005963A1 (en) * 2017-06-27 2019-01-03 The University Of Chicago USE OF ACTIVIN TO DETECT POST-PARTUM CARDIAC DYSFUNCTION

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, vol. 124, no. 21, JPN6025034653, 2011, pages 14691, ISSN: 0005672230 *
CIRCULATION, vol. 142, no. 3, JPN6025034654, 12 November 2020 (2020-11-12), pages 14803, ISSN: 0005672231 *

Also Published As

Publication number Publication date
CN116249713A (zh) 2023-06-09
CA3189147A1 (en) 2022-02-24
MX2023001734A (es) 2023-03-31
AU2021327238A9 (en) 2024-06-06
US20220056119A1 (en) 2022-02-24
WO2022040461A1 (en) 2022-02-24
IL300362A (en) 2023-04-01
US20250277021A1 (en) 2025-09-04
KR20230051683A (ko) 2023-04-18
AU2021327238A1 (en) 2023-04-27
EP4200017A1 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
JP7796918B2 (ja) エボラウイルス糖タンパク質に対するヒト抗体
JP6845876B2 (ja) 抗ｉｌ−３３抗体及びその使用
JP7141333B2 (ja) 抗－ａｎｇｐｔｌ８抗体及びその使用
US9657099B2 (en) Anti-glucagon antibodies
US9926369B2 (en) Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody
TWI824372B (zh) 活化瘦素受體的抗原結合蛋白
US20180008672A1 (en) Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
US20110027286A1 (en) High Affinity Human Antibodies to Human Angiopoietin-2
TWI613215B (zh) 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
JP7042816B2 (ja) レプチン受容体をアンタゴナイズする抗原結合性タンパク質
BR122020011337B1 (pt) Anticorpos humanos para o receptor de glucagon, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico isolada e vetor de expressão
JP2021507677A (ja) 抗ｔｒｋｂモノクローナル抗体および使用の方法
JP2023526233A (ja) 抗ｇｌｐ１ｒアンタゴニスト抗体およびその使用方法
US20180057580A1 (en) Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension
US20140112930A1 (en) Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
US20250277021A1 (en) Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A Antagonists
KR20240099304A (ko) 인자 xi a2 도메인 결합 항체 및 이의 사용 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260226